Compare Albemarle Corp. (ALB) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Stryker Corporation — how do they compare? Albemarle Corp. trades at $128.07 (market cap $15.27B), while Stryker Corporation trades at $346.82 (market cap $133.54B). The key difference: Stryker Corporation is far larger — about 8.7× Albemarle Corp.'s market cap, and Albemarle Corp. pays the higher dividend (1.27%). Which is the better fit depends on your goals.
| ALB | SYK | |
|---|---|---|
Market Cap | $15.27B | $133.54B |
Sector | Basic Materials | Technology |
52-Week High | $215.62 | $394.34 |
52-Week Low | $72.58 | $282.58 |
Enterprise Value | $17.75B | $145.01B |
Dividend Yield | 1.27% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) trades at $128.29, down 2.23% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company reported strong Q2 2026 results with EPS of $3.75 beating estimates by 17%, driven by improved lithium pricing and specialty chemicals performance. Despite recent profitability challenges with negative net income in 2025, cash flow generation remains healthy at $1.28B from operations.
Analyst consensus leans positive with 42% buy ratings and $184.50 price target representing 44% upside potential. Key risks include lithium price volatility and Q3 margin pressure, while catalysts include sustained demand for energy storage solutions and ongoing balance sheet improvements through debt reduction.
Stryker (SYK) trades at $345.86, up slightly by 0.01% today, with a bullish technical signal and strong analyst support. The company reported a Q2 2026 earnings beat with $3.69 EPS versus $3.49 expected, driven by 9% organic sales growth and recovery from a cyber incident. Fundamentals show robust profitability with a 14.43% net income margin and 16.51% ROE, though valuation ratios like a P/E of 36.08 are elevated.
Outlook remains positive with raised guidance and new product launches like Mako RPS expanding market reach. Key risks include execution challenges post-cyberattack and competitive pressures. The consensus price target of $379.44 implies ~10% upside, supported by 74% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
